Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.54 |
| ▸ | TACR1 | P25103 | 5/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7812359 | 0.84 | TACR1 (0.54) | SLC6A4TACR1SLC6A2SLC6A3HRH3 | |
| SCHEMBL6160138 | 0.84 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3CHRM2CHRM3 | |
| SCHEMBL28787509 | 0.84 | MEN1 (0.52) | SLC6A4TACR1SLC6A2SLC6A3MEN1 | |
| SCHEMBL9785709 | 0.83 | SLC6A4 (0.53) | SLC6A4TACR1SLC6A2SLC6A3CHRM2 | |
| Hydrochloric Acid SCHEMBL22797859 | 0.83 | SLC6A2 (0.53) | SLC6A4SLC6A2SLC6A3CHRM2CHRM3 | |
| Hydrochloric Acid SCHEMBL9785704 | 0.82 | SLC6A4 (0.52) | SLC6A4TACR1SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL28787507 | 0.81 | TACR1 (0.64) | SLC6A4TACR1SLC6A2SLC6A3HRH3 | |
| SCHEMBL5383249 | 0.80 | SLC6A4 (0.48) | SLC6A4TACR1SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL7259641 | 0.76 | SLC6A4 (0.38) | SLC6A4TACR1SLC6A2SLC6A3CHRM2 | |
| SCHEMBL9785728 | 0.76 | QPCT (0.52) | SLC6A4TACR1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786308-B2 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786308-B2 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786308-B2 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080090826-A9 | Muscarinic modulators | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2008-04-17 | — | — | US | disclosed |
| US-20080090826-A9 | Muscarinic modulators | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2008-04-17 | — | — | US | disclosed |
| US-20080090826-A9 | Muscarinic modulators | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2008-04-17 | — | — | US | disclosed |
| US-7348324-B2 | Cyclic amine compounds as CCR5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-25 | — | — | US | disclosed |
| EP-1886994-A1 | Cyclic amine compounds as CCR5 antagonists | Takeda Pharmaceutical Company Limited (JP) | 2008-02-13 | — | — | EP | disclosed |
| EP-1863490-A2 | MUSCARINIC MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070054911-A1 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2007-03-08 | — | — | US | disclosed |
| WO-2006105035-A2 | MUSCARINIC MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-10-05 | — | — | WO | disclosed |
| EP-0891332-B1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | TOBIRA THERAPEUTICS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-6562978-B1 | N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-05-13 | — | — | US | disclosed |
| CN-1390201-A | cyclic amine compounds as CCR5 antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | CN | disclosed |
| US-6465491-B2 | NITRIC OXIDE SYNTHASE INHIBITOR; NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-10-15 | — | — | US | disclosed |
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | LOWE JOHN A (US) | 2001-10-25 | — | — | US | disclosed |
| US-6235747-B1 | NITRIC OXIDE SYNTHASE INHIBITOR | PFIZER INC. | 2001-05-22 | — | — | US | disclosed |
| EP-0891332-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER INC. (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036871-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER INC. (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054911-A1 | Muscarinic modulators | CHRM3, CHRM5, CHRM4 | SLC6A4 950/4885TACR1 56/4885SLC6A2 772/4885 |
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | NOS2, NOS3, NOS1 | SLC6A4 117/4885TACR1 837/4885SLC6A2 47/4885 |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | CCR5, CCR1, CCR3 | SLC6A4 559/4885TACR1 57/4885SLC6A2 459/4885 |
| US-20080090826-A9 | Muscarinic modulators | CHRM3, CHRM5, CHRM4 | SLC6A4 950/4885TACR1 56/4885SLC6A2 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.